Merck(US:MRK) Yahoo Finance·2026-01-21 12:10Core Insights - Merck & Co., Inc. (NYSE:MRK) is recognized as one of the undervalued stocks by Goldman Sachs, indicating potential investment opportunities [1] Analyst Sentiment - As of January 16, 2026, approximately 60% of analysts maintain a bullish outlook on Merck, despite a modest consensus price target of $115.00, reflecting a 3.60% upside [2] - Wolfe Research upgraded Merck from 'Peer Perform' to 'Outperform' on January 8, 2026, raising the price target to $135.00, driven by updates in the valuation model that consider the company's late-stage pipeline and potential label expansions [3] Strategic Developments - Merck is reportedly exploring the acquisition of Revolution Medicines, a cancer drug developer, with a potential deal valued between $28 billion and $32 billion, which would enhance its oncology pipeline amid patent risks for Keytruda expected later in the decade [4] - The company has a strong oncology franchise and is expanding its late-stage pipeline across various therapeutic areas, positioning itself favorably in the healthcare market [5]